Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 85725 | 3.685 |
09:34 ET | 64460 | 3.7098 |
09:36 ET | 35021 | 3.72 |
09:38 ET | 90555 | 3.77 |
09:39 ET | 46198 | 3.77 |
09:41 ET | 70187 | 3.75 |
09:43 ET | 115661 | 3.775 |
09:45 ET | 61022 | 3.79 |
09:48 ET | 71831 | 3.82 |
09:50 ET | 62171 | 3.81 |
09:52 ET | 37502 | 3.79 |
09:54 ET | 93513 | 3.775 |
09:56 ET | 62397 | 3.77 |
09:57 ET | 26228 | 3.79 |
09:59 ET | 54858 | 3.8 |
10:01 ET | 90970 | 3.815 |
10:03 ET | 41425 | 3.835 |
10:06 ET | 67838 | 3.835 |
10:08 ET | 143002 | 3.84 |
10:10 ET | 277256 | 3.8599 |
10:12 ET | 94022 | 3.87 |
10:14 ET | 60124 | 3.865 |
10:15 ET | 52394 | 3.85 |
10:17 ET | 53252 | 3.86 |
10:19 ET | 23449 | 3.86 |
10:21 ET | 21508 | 3.855 |
10:24 ET | 29347 | 3.86 |
10:26 ET | 55267 | 3.87 |
10:28 ET | 50339 | 3.87 |
10:30 ET | 21732 | 3.87 |
10:32 ET | 111708 | 3.8699 |
10:33 ET | 23487 | 3.86 |
10:35 ET | 161910 | 3.845 |
10:37 ET | 26619 | 3.84 |
10:39 ET | 11210 | 3.85 |
10:42 ET | 49855 | 3.86 |
10:44 ET | 95631 | 3.855 |
10:46 ET | 59884 | 3.855 |
10:48 ET | 87153 | 3.85 |
10:50 ET | 203287 | 3.845 |
10:51 ET | 138086 | 3.85 |
10:53 ET | 18081 | 3.845 |
10:55 ET | 15859 | 3.84 |
10:57 ET | 18159 | 3.845 |
11:00 ET | 75615 | 3.855 |
11:02 ET | 201911 | 3.9 |
11:04 ET | 43283 | 3.918 |
11:06 ET | 83754 | 3.885 |
11:08 ET | 28612 | 3.885 |
11:09 ET | 36108 | 3.9 |
11:11 ET | 345279 | 3.85 |
11:13 ET | 36614 | 3.855 |
11:15 ET | 43458 | 3.845 |
11:18 ET | 12491 | 3.84 |
11:20 ET | 24068 | 3.845 |
11:22 ET | 31451 | 3.84 |
11:24 ET | 14328 | 3.84 |
11:26 ET | 26518 | 3.845 |
11:27 ET | 19701 | 3.84 |
11:29 ET | 33313 | 3.845 |
11:31 ET | 171939 | 3.79 |
11:33 ET | 33753 | 3.79 |
11:36 ET | 41240 | 3.785 |
11:38 ET | 71619 | 3.809 |
11:40 ET | 14606 | 3.8 |
11:42 ET | 38291 | 3.8 |
11:44 ET | 49481 | 3.8 |
11:45 ET | 42378 | 3.8 |
11:47 ET | 53877 | 3.795 |
11:49 ET | 44328 | 3.8 |
11:51 ET | 32563 | 3.8 |
11:54 ET | 37103 | 3.8 |
11:56 ET | 78197 | 3.8 |
11:58 ET | 20679 | 3.805 |
12:00 ET | 48046 | 3.795 |
12:02 ET | 16282 | 3.805 |
12:03 ET | 7613 | 3.805 |
12:05 ET | 21015 | 3.8 |
12:07 ET | 204457 | 3.75 |
12:09 ET | 26000 | 3.755 |
12:12 ET | 52820 | 3.755 |
12:14 ET | 77926 | 3.76 |
12:16 ET | 141545 | 3.74 |
12:18 ET | 39401 | 3.74 |
12:20 ET | 2020 | 3.745 |
12:21 ET | 36501 | 3.725 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.1B | -10.8x | --- |
Vera Therapeutics Inc | 2.1B | -19.6x | --- |
CG Oncology Inc | 2.2B | -32.0x | --- |
Celldex Therapeutics Inc | 2.2B | -11.8x | --- |
Rocket Pharmaceuticals Inc | 1.9B | -7.6x | --- |
Agios Pharmaceuticals Inc | 2.1B | -6.8x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.1B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.42 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -10.8x |
Price/Sales (TTM) | 4,049.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.